Sign up to save your podcasts
Or
Share Perspectives on Selected Myasthenia Gravis Posters and Abstracts From AANEM
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Perspectives on Selected Myasthenia Gravis Posters and Abstracts From AANEM
Perspectives on Selected Myasthenia Gravis Posters and Abstracts From AANEM episodes
- 2 min
- Long-Term Safety and Efficacy of Zilucoplan in Generalized Myasthenia Gravis 120-Week Interim Analysis of RAISE-XT
Author: Howard, JF, et al.
Overview Provided by Nicolas Silvestri, MD3 min - Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 VIVACITY-MG3 Study
Author: Strober J, et al.
Overview Provided by Nicolas Silvestri, MD4 min - Concomitant Corticosteroid Use with Ravulizumab in Adults with Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Phase 3 CHAMPION-MG Open-Label Extension Final Results
Author: Nicolle M, et al.
Overview Provided by Nicolas Silvestri, MD4 min - Cyclic and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT
Author: Habib AA, et al
Overview Provided by Nicolas Silvestri, MD4 min - 3 min
About Perspectives on Selected Myasthenia Gravis Posters and Abstracts From AANEM
From the publisher's feed
Myasthenia gravis, an autoimmune disease characterized by fluctuating muscle weakness, greatly impacts patients’ functioning and activities of daily living. Important treatment advances continue to be…
made to reduce patient burden of disease and overcome safety, efficacy, and other limitations of available therapies. Join Nicholas Silvestri, MD, as he reports on research results of some of these advances presented at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.